FORGOTTEN HISTORY: 7 | History Defined

Generic Ozempic drugs are about to flood the market

Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high prices

The Independent UK · Jan 15

Off the Scales by Aimee Donnellan review – inside the Ozempic revolution

A fascinating deep dive into the discovery, use and implications of a revolutionary new treatment

The Guardian - UK · Jan 15

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs

The Independent UK · Jan 13

From injectables to pills: how the new Wegovy tablet will change the weight loss market forever

IN FOCUS: The launch of an oral semaglutide pill approved for weight loss represents a new frontier for GLP-1 drugs. Katie Rosseinsky looks at how the landscape is changing

The Independent UK · Jan 7

Wegovy Weight-Loss Pill Hits US Market — How Much It Costs, Where to Buy It and How Effective It Really Is

Novo Nordisk's Wegovy, the first oral GLP-1 weight-loss pill, is now in 70,000+ US pharmacies, costing $5 (£4) to $10 (£7) per day.

International Business Times UK · Jan 6

Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war

First and only GLP-1 pill on the market costs significantly less than injectable versions

The Guardian - UK · Jan 5

Novo Nordisk's Future Vision on 'Weight Loss' Wins Scientists, Tests Wall Street's Patience

Novo Nordisk's long-term strategy for weight-loss treatments has earned praise from scientists, even as investors grow cautious about timelines, competition and near-term returns.

International Business Times UK · Dec 30, 2025

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Barchart · Dec 25, 2025

Asian shares are mixed after US stocks drift to more records

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas

The Independent UK · Dec 25, 2025

Wegovy Pill Launch Promises Change — But Its Cost and What It Does Could Decide Who Gets Help

The Wegovy pill has been approved, but questions over cost and access could shape who benefits from the new oral weight-loss treatment.

International Business Times UK · Dec 23, 2025